Tamara J. Laskowski, PhD
Houston, Texas, United States
1K followers
500+ connections
About
Well-established scientist with strong business acumen and technical leadership…
Articles by Tamara J.
-
Defining the Next Generation of Immune-oncology Cell Therapy
Defining the Next Generation of Immune-oncology Cell Therapy
By Tamara J. Laskowski, PhD
Activity
-
Cell Therapy IPO and M&A Activity From 2013 to Today The dominant strategy has evolved alongside the broader capital markets: Early on we saw more…
Cell Therapy IPO and M&A Activity From 2013 to Today The dominant strategy has evolved alongside the broader capital markets: Early on we saw more…
Liked by Tamara J. Laskowski, PhD
-
𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐫𝐞𝐚𝐜𝐡𝐞𝐬 𝐢𝐭𝐬 𝐭𝐮𝐫𝐧𝐢𝐧𝐠 𝐩𝐨𝐢𝐧𝐭: 2 solid tumour breakthroughs in 8 months 👇 On Friday, we celebrated a BIG…
𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐫𝐞𝐚𝐜𝐡𝐞𝐬 𝐢𝐭𝐬 𝐭𝐮𝐫𝐧𝐢𝐧𝐠 𝐩𝐨𝐢𝐧𝐭: 2 solid tumour breakthroughs in 8 months 👇 On Friday, we celebrated a BIG…
Liked by Tamara J. Laskowski, PhD
-
Join Lonza, a global leader in life sciences, as a key member of our Legal team. Utilize your expertise to craft impactful business solutions and…
Join Lonza, a global leader in life sciences, as a key member of our Legal team. Utilize your expertise to craft impactful business solutions and…
Liked by Tamara J. Laskowski, PhD
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
The University of Texas Health Science Center at Houston (UTHealth)
-
Activities and Societies: Career Development Council-Association for Women in Science; Scientific Editor-MD Anderson Cancer Center Trainee Editing Service; Elevator Speech Coach-MD Anderson Cancer Center; Lecturer, MDACC School of Heath Professions; UT GSBS Association of Minority Biomedical Researchers; Society for Immunotherapy of Cancer; American Society for Gene and Cell Therapy; National Association for Women in Science; MD Anderson Cancer Center Post-Doctoral Association; Golden Key International Honor Society
-
-
Publications
-
Activated B cells suppress T-cell function through metabolic competition
Journal for ImmunoTherapy of Cancer
This work describes a mechanism by which activated B cells mediate T cell suppression through metabolic competition, and suggests a correlation between metabolically-active tumor-associated B cells and poor response to ICB therapy in patients with Melanoma.
Other authors -
-
Trogocytosis-mediated tumor relapse after CAR-NK cell therapy prevented by inhibitory CARs
Nature Medicine
See publicationIn this work, we report a dual-CAR-NK cell product controlled by a logic-gate-mimicking inhibitory CAR that improves tumor-targeting specificity, reduces cell dysfunction, and prevents tumor relapse.
-
Natural killer cells in antitumour adoptive cell immunotherapy
Nature Reviews Cancer
Review article focused on the emerging role of NK cells in immuno-oncology. This manuscript describes the various approaches to augment NK cell cytotoxicity and longevity, evaluates challenges and opportunities for NK cell therapeutics, and provides a perspective on how lessons learned from the clinic will guide the design of next-generation NK cell products that will address the unique complexities of each cancer.
Other authors -
-
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021
Journal of Translational Medicine
See publicationExpert-led summary discussion of data presented at the 2022 Immunotherapy Bridge co-organized with the Society for Immunotherapy of Cancer. Discussion addresses several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers.
-
Engineering new killers: bringing NK cells to the battle against cancer
Cell and Gene Therapy Insights
Editorial article discussing the rise of NK cells in adoptive cell therapy and highlighting challenges and opportunities.
Other authors -
-
Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies
American Society of Clinical Oncology (ASCO)
Discussing the requirements for successful implementation of cell therapy programs and for the transition of cell therapies from lab to clinic.
Other authors -
-
Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy
Cytotherapy - International Society for Cell and Gene Therapy
-
Rigor and Reproducibility of Cytometry Practices for Immuno-Oncology: A multifaceted challenge
Cytometry Part A - International Society for Advancement of Cytometry
Article provides guidelines for designing and implementing cytometry-based studies with high rigor to ensure data reliability and reproducibility.
Other authors -
-
Unlocking the potential of Cell Therapies for Solid Tumors
Interview with Cell & Gene Therapy Insights/ Bioinsights
See publicationImmunotherapy is a ground-breaking discovery that has tremendously impacted the oncology field and strengthened the hope that we can indeed cure cancer. In this work, we discuss the successes and challenges in this field, and highlight the advancements in technology which allow scientists to move forward with new strategies to overcome the inherent complexities of this disease.
-
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors
PLOS One
In this work, we report the functionality of CAR immunoreceptors comprised of mix-and-matched versions of VH and VL scFv domains targeting CD123 surface marker in AML tumors.
In particular, through flow-cytometric analysis of CAR T-cells in killing assays, we described the activation and cytotoxic potential induced by each immunoreceptor format generated in this study.Other authors -
-
Gene Correction of iPSCs from a Wiskott-Aldrich Syndrome Patient Normalizes the Lymphoid Developmental and Functional Defects
Stem Cell Reports / Cell Press
See publicationIn this work we describe a gene therapy approach for repairing germline mutations in induced pluripotent stem cells derived from a Wiskott-Aldrich Syndrome patient. Furthermore, we report our findings that genetic correction of the WAS locus resulted in the normalization of T- and NK- lymphocyte development, and in restoration of normal NK cell immune function.
Honors & Awards
-
Review Editor - Frontiers in Bioengineering
Frontiers in Bioengineering
-
Review Editor - Editorial Board of Cancer Immunity and Immunotherapy
Frontiers in Immunology
Member of the Editorial Board of Cancer Immunity and Immunotherapy, a specialty section of Frontiers in Immunology and Frontiers in Oncology
-
Guest Editor - October 2021 Spotlight Edition of Cell and Gene Therapy Insights
-
-
Ask-an-expert webinar speaker - Understanding and applying good flow cytometry practices
Champions Oncology
Educational webinar focused on instructing early flow cytometry users the foundational principles for successful use of flow cytometry in immuno-oncology studies.
-
Invited speaker at MD Anderson's 2019 Spark Entrepreneurship Summit
MD Anderson Cancer Center
Invited to give speak to scientists and entrepreneurs about my perspective as an award-winning fellow of the National Science Foundation Innovation Corps program for commercialization of scientific discoveries.
Talk title: "No Longer The Great Divide: Academia’s Modern Perspective On Industry" -
Editorial Advisory Board Member - Cell and Gene Therapy Insights
BioInsights
-
MD Anderson Employee Recognition Award
Department of Immunology
For outstanding performance and timely completion of goals associated with drug development project.
-
Invited panelist: Immunotherapy and Cell Therapy Panel discussion
Sartorius
Panel of experts from academia and biotech/pharma joining together to discuss the current successes and challenges of cellular immunotherapy, focusing on developments in CAR T-cell and NK immunotherapies.
-
Invited Speaker - Research Xchange Forum - Science/AAAS Headquarters Washington DC
-
Biomedical Science-focused meeting at Science/AAAS Headquarters uniting scientists from international institutions (Industry and Academia)to discuss scientific progress and technology innovations in the Immunotherapy landscape.
Watch panelist talks at: https://www.sartorius.com/us-en/company/conferences/rxf-2019 -
MD Anderson Employee Recognition Award
Department of Immunology
For contributions made toward advancing clinical projects.
-
Diaspora of Innovation in Science and Technology Award
Government of Brazil - The Brazilian Embassy in Washington DC
Awarded this prize in recognition of scientific accomplishments and contributions to science and technology innovation.
-
Interview with Cell & Gene Therapy Insights - UK
Cell & Gene Therapy Insights
Immunotherapy is a ground-breaking discovery that has changed the oncology landscape. This project focuses on educating the broad scientific community on the progress, the challenges, and the new directions scientists are taking as we continue to investigate new strategies for defeating this very complex disease.
Learn more at:
http://insights.bio/cell-and-gene-therapy-insights/?bio_journals=unlocking-the-potential-of-car-t-therapies-for-solid-tumors
-
NSF Innovation Corps Regional Program Award- 2017
MD Anderson I-Corps Regional Program
Award given for outstanding performance in the National Science Foundation (NSF) Innovation Corps Program for technology commercialization and entrepreneurship.
-
Invited Speaker - International Society for Cell Therapy Annual Conference - London, UK
International Society for Cell Therapy
Invited to speak about our new, proprietary platforms for multi-parameter high-throughput flow cytometric analysis of CAR T-cell and NK cell cytotoxicity.
-
Invited Speaker - IntelliCyt Insight- Flow Cytometry Meeting - San Diego and San Francisco, CA
-
“Out with Chromium, in with flow: Characterizing CAR T-cell cytotoxic function through high-throughput flow cytometry”
-
Invited Webinar Speaker
Drug Discovery World
“Improving the Assessment of Cytotoxic Function of Engineered Lymphocytes”
https://www.ddw-online.com/webinars/p316760-applications-of-a-rapidhigh-contentplate-based-platform-for-functional-and-phenotypic-screening-of-small-moleculessars-and-cell-based-therapeutics.html
-
Invited Speaker - CAR-TCR Summit - Boston, MA
-
“Improving analysis of CAR T-cell cytotoxic function through High-Throughput Multi-Parameter Flow Cytometry”
-
Best Elevator Speech Award
MD Anderson Cancer Center
Languages
-
English
Native or bilingual proficiency
-
Portuguese
Native or bilingual proficiency
-
Spanish
Professional working proficiency
Recommendations received
1 person has recommended Tamara J.
Join now to viewMore activity by Tamara J.
-
"I believe we have the ability to create a new therapeutic class to target diseases that haven't been treatable before." Our CEO, Sarah Hein, was…
"I believe we have the ability to create a new therapeutic class to target diseases that haven't been treatable before." Our CEO, Sarah Hein, was…
Liked by Tamara J. Laskowski, PhD
-
We’re excited to cheer on The University of Texas Health Science Center at Houston (UTHealth) School of Public Health alumna Gabby Thomas, MPH, who…
We’re excited to cheer on The University of Texas Health Science Center at Houston (UTHealth) School of Public Health alumna Gabby Thomas, MPH, who…
Liked by Tamara J. Laskowski, PhD
-
A toast with veteran space scientist Cathy Yeung, the new guy ( yours truly) and implementation partners Jana Stoudemire Axiom Space & Stefanie…
A toast with veteran space scientist Cathy Yeung, the new guy ( yours truly) and implementation partners Jana Stoudemire Axiom Space & Stefanie…
Liked by Tamara J. Laskowski, PhD
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More